The Largest Non-Fatal Driver of Healthspan Loss

Approximately fifty million U.S. adults live with chronic pain; twenty million have high-impact chronic pain. The opioid epidemic killed approximately eighty thousand Americans per year at peak — itself a pain-driven mortality story. The recent regulatory approval of the first selective sodium-channel-targeting non-opioid analgesic class opened the post-opioid era. The CureForge Pain & Chronic Suffering Institute is the federation’s research engine for that future. Eleven specialized AI systems collaborate across pain-pathway mechanism analysis, non-opioid analgesic design, neuropathic pain, migraine therapeutics, fibromyalgia, chronic fatigue syndrome and the related post-viral conditions, Long COVID pain and fatigue coordinated with the infectious disease institute, end-of-life pain management, opioid tapering coordinated with the mental health institute, inflammaging-pain cross-talk, and functional pain imaging biomarkers.

Value proposition:

• Non-opioid analgesic design beyond the first regulatory-approved class
• Long COVID and chronic-fatigue research as first-class research surface
• Functional pain imaging biomarkers as objective measurement